Drug intelligence / Profile preview

MNS-FTD247

Development stage: Preclinical
Lead developer: Prediction BioSciences
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intranasal

Overview

MNS-FTD247 (also known as MNS-FTD2) is a preclinical-stage, exosome-based therapeutic candidate being developed by Prediction BioSciences and its R&D laboratory, Mosaic Neurosciences, for the treatment of frontotemporal dementia (FTD). The therapy utilizes a brain cell-type-specific exosome platform designed to cross the blood-brain barrier and deliver therapeutic cargo directly to targeted brain cells. It is designed to act as a progranulin (PGRN) replacement therapy to address progranulin deficiency, which is a major genetic cause of behavioral variant frontotemporal dementia (bvFTD), without promoting the tumorigenic properties associated with wild-type progranulin.

Beyond the preview

Go deeper on MNS-FTD247.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MNS-FTD247.

Explore the full profile